The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Summit Therapeutics (NASDAQ:SMMT) stock spikes as Citi upgrades the company, citing its lead asset ivonescimab, developed ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Summit Therapeutics (NASDAQ: SMMT) is one of those stocks that have been quite explosive: The share price of the ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet ...

The following is a summary of “Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration,” published in the March 2025 issue of British Journal ...

Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the ...

Blindness or vision loss is a growing concern among older adults, and one of the leading causes is a condition known as ...

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that ...

HC Wainwright downgraded shares of Opthea (NASDAQ:OPT – Free Report) from a buy rating to a neutral rating in a research report released on Tuesday morning, MarketBeat.com reports. The firm currently ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...